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RADIATION THERAPY AND EXPANDER-IMPLANT BREAST
RECONSTRUCTION: ANALYSIS OF TIMING AND COMPLICATIONS. Rachel
B. Lentz, Reuben Ng, Susan A. Higgins, Michael M. Matthew, Stefano Fusi, and
Stephanie L. Kwei. Section of Plastic Surgery, Department of Surgery, Yale
University, School of Medicine, New Haven, CT.

The optimal timing of expander-implant exchange in the setting of post
mastectomy radiation remains unclear with prior reports yielding inconsistent and
variable results. The purpose of this study was to characterize complications
associated with the sequencing of expander-implant breast reconstruction before
or after radiation therapy and to compare the outcomes between early (< 4
months) and late (>4 months) expander-implant exchange in the subset of
patients who received radiation prior to exchange.
The medical records of all patients receiving post-mastectomy radiation
therapy in the setting of tissue expander-implant breast reconstruction between
June 2004 – June 2011 at Yale-New Haven hospital were reviewed
retrospectively. Patients were first classified as having undergone expanderimplant exchange prior to the initiation of radiation or after the completion of
radiation. Patients who underwent expander-implant exchange after radiation
were then classified as having undergone exchange early (<4 months following
radiation) or late (>4 months following radiation). All complications requiring
additional surgery or hospitalization were recorded.
Fifty-five eligible patients were identified as having undergone 56 twostage tissue expander-implant breast reconstructions. 22 reconstructions
underwent exchange prior to radiation and 34 reconstructions underwent
exchange following radiation. There was no significant difference in overall

complication rate (54.55% vs 47.06%, p=0.785) or reconstruction failure rate
(13.64% vs 20.59%, p=0.724) between the two cohorts. 20 reconstructions
underwent exchange <4 months following radiation and14 underwent exchange
>4 months following radiation. There was no significant difference in overall
complication rate (40% vs 57.14%, p=0.487) or failure rate (25% vs 14.29%,
p=0.672) between the two groups. Trends suggest a higher rate of infection in
patients who underwent earlier exchange (30% vs 14.29%, p=0.422) and a
higher rate of capsular contracture in patients who underwent later exchange
(5% vs 21.43%, p=0.283), however statistical significance was not reached.
Our findings suggest that neither the sequencing nor timing of expanderimplant exchange in the setting of radiation has an impact on overall complication
or reconstruction failure rate. However, the timing of exchange may impact the
type of complication encountered.
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I.

INTRODUCTION

Breast cancer remains the most commonly diagnosed cancer in women. Recent
statistics indicate that 1 in every 8 American women will develop breast cancer at
some point over the course of her lifetime(1). Over the past decade, there has
been a marked rise in the number of women seeking breast reconstruction as
part of their breast cancer treatment, with over 96,000 breast reconstruction
operations performed in the United States in 2011 alone (2). During this same
time period, the prevalence of adjuvant oncologic therapies, including chemo-and
radiation therapies has increased as well. Ultimately, the management of breast
cancer today requires a multidisciplinary approach, and it has become imperative
to gain a better understanding of the impact of breast reconstruction on adjuvant
treatments, and the impact that these treatments have on reconstruction
outcomes.

Following the diagnosis of breast cancer, a patient may be referred to a medical
oncologist for hormonal or chemotherapy, a breast surgeon for a lumpectomy or
mastectomy, a radiation oncologist for radiation therapy, and a reconstructive
surgeon to explore their reconstructive options. Care must be taken to
appropriately coordinate all of these elements in order to optimize both oncologic
treatment and reconstructive results. Figure 1 depicts a possible timeline of
breast cancer management.
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FIGURE 1. Breast Cancer Management Timeline
Several variables must be coordinated in the management of breast cancer
patients. Neoadjuvant chemotherapy may be administered prior to mastectomy in
order to shrink the primary tumor size. Reconstruction may be performed
immediately at the time of mastectomy or in a delayed fashion, following the
completion of adjuvant therapies. Radiation can be administered before or after
reconstruction.

Post-mastectomy radiation therapy is becoming an increasingly common part of
breast cancer treatment today; it has been shown to decrease the risk of
locoregional recurrence and is associated with prolonged survival times (3).
Current absolute indications for radiation therapy include: presence of four or
more positive lymph nodes, tumor size greater than 5cm, and positive margins
following mastectomy (3-6). Factors associated with a higher risk of recurrence
include: age at diagnosis < 40, histological grade 3 tumor, presence of
lymphovascular invasion, <6 nodes removed during axillary dissection, significant
nodal extracapsular spread, and presence of 1-3 positive nodes(7). Individuals
with these characteristics are now being offered radiation at an increasing rate.

As a result, there has been a marked rise in the number of patients presenting for
breast reconstruction who will also undergo radiation therapy as part of their
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breast cancer treatment. Implant-based breast reconstruction in the setting of
post-mastectomy radiation therapy remains a challenge. Radiation therapy
engenders changes in mastectomy flap perfusion, which may result in infection,
tissue necrosis, capsular contracture, implant extrusion, wound dehiscence, and
complete reconstructive failures (8-11). The deleterious effect of radiation tends
to be more pronounced with prosthetic reconstruction as compared to autologous
reconstruction(12-14). However, autologous reconstruction is not always a viable
option for patients. Autologous reconstruction necessitates an additional donor
site and often requires a longer post-operative hospitalization and recovery
period. Subsequently, implant based breast reconstruction remains the most
popular option for immediate breast reconstruction today(15).

The majority of prosthetic reconstructions are performed as two stage tissue
expander-implant reconstructions. Typically, the tissue expander is placed under
the pectoralis major muscle, within the breast pocket at the time of mastectomy.
Immediate placement of the tissue expander helps to preserve the integrity of the
breast skin envelope and maintain the patient’s natural inframammary fold.
Periodic expansions of the tissue expanders occur over the course of weeks to
months. Once the breast has reached an adequate volume and the soft tissue
pocket has been appropriately expanded, the tissue expander is removed and
exchanged for a permanent implant (figure 2).
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FIGURE 2. Tissue Expander-Implant Breast Reconstruction
Typically the tissue expander is placed at the time of mastectomy. Following
period expansions, the tissue expander is replaced with a permanent implant.

The necessity of radiation therapy complicates the typical breast reconstruction
timeline. Given the high risk of complications associated with radiation, many
surgeons advocate delaying reconstruction until all adjuvant therapies have been
completed (12, 16). In Kronowitz’s 2007 review of immediate versus delayed
reconstruction, he reports that if radiation is required, delayed reconstruction is
usually the best course, however, if radiation is not required, immediate
reconstruction should be performed (16). The benefits of immediate breast
reconstruction are well documented in the plastic surgery literature. Patients who
undergo immediate reconstruction have been shown to have improved
psychosocial well-being and superior final aesthetics when compared to those
who undergo delayed reconstructions (17, 18).

Unfortunately, the requirement of radiation therapy in patients who are clinically
node negative is often unknown at the time of mastectomy. Final pathology

5
reports may not be available until days later. In patients undergoing tissue
expander-implant reconstruction, by the time the necessity of radiation has been
determined, the tissue expander has already been placed.

At this point, the plastic surgeon and radiation oncologist are faced with the
question of how to optimally coordinate the timing of the rest of the reconstruction
with radiation treatment. Is it better to complete the two-stage reconstruction and
perform the exchange to permanent implant prior to radiation, thus irradiating the
permanent implant, or to perform the exchange following completion of radiation,
thus irradiating the tissue expander?

Although complications of implant based breast reconstruction in the setting of
radiation are well described, little is known about the physiological and temporal
effects of how radiation therapy influences the sequence of two-stage expanderimplant reconstruction. Prior studies that have attempted to answer this question
have yielded inconclusive and inconsistent results with some reporting exchange
prior to radiation results in fewer complications(19), while others report no
difference(20-22).

Additionally, from an oncologic perspective, we know there is a therapeutic
benefit to administering radiation soon after mastectomy. A 2003 review
examining the impact of delayed initiation of radiation found that the 5-year local
recurrence rate was significantly higher in patients whose radiation was started
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more than 8 weeks after surgery(23). Does performing expander-implant
exchange prior to radiation contribute towards a delay in initiation of radiation
therapy? To date, no previous study has investigated this question.

Lastly, for patients who undergo exchange following the completion of radiation,
there is limited data that describes the optimal time to wait following completion
of radiation before proceeding with exchange to permanent implants. Most
surgeons recommend waiting between 3 – 6 months following the completion of
radiation before proceeding with exchange to permanent implant. However,
these time frames are largely subjective and not evidence based.
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Statement of Purpose

Purpose
The purpose of this study was to investigate and characterize the impact of
timing of expander-implant exchange and post-mastectomy radiation therapy on
breast reconstruction outcomes.

Specific Aims
The specific aims of this study were:
1.

to characterize the complications associated with the sequencing of
expander-implant exchange before or after post-mastectomy
radiation therapy1,

2.

to determine the impact of sequencing of expander-implant
exchange on delivery of radiation therapy, and

3.

to compare the outcomes between early (< 4 months) and late (>4
months) expander-implant exchange in the subset of patients who
received post-mastectomy radiation therapy prior to expanderimplant exchange.

1

To clarify, if the expander-implant exchange occurs prior to radiation, then the
permanent implant is getting irradiated. If the expander-implant exchange occurs
after radiation, then the tissue expander is getting radiated. Another way to
interpret the first aim of our study is: to characterize the complications associated
with radiating a permanent implant versus radiating a tissue expander.
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Hypotheses
The null hypotheses were:
1.

sequencing of expander-implant exchange before or after postmastectomy radiation does not have an impact on complications,

2.

sequencing of expander-implant exchange does not impact the
delivery of radiation therapy, and

3.

there is no difference between the outcomes of patients who
undergo early or late expander-implant exchange.

As alternative hypotheses, the investigators posited that:
1.

the sequencing of expander-implant exchange would impact the
complications seen in reconstruction patients,

2.

the sequencing of expander-implant exchange would impact the
timing to radiation therapy administration, and

3.

there would be a difference in outcomes in patients who undergo
early versus late expander-implant exchange following radiation.
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II.

METHODS

Under the auspices of the Yale University School of Medicine’s Human
Investigation Committee, we identified all patients who underwent tissue
expander-implant breast reconstruction at Yale New Haven Hospital and
received post-mastectomy radiation therapy as part of their breast cancer
treatment between June 2004 – June 2011.

A de-identified database was then created and maintained by the thesis author
for the purposes of this study. An extensive retrospective review of patient
medical records was performed in order to screen for possible study inclusion
and collect demographic, therapeutic, and operative data for subsequent
analysis.

In total, seventy-three patients were identified as having undergone immediate
tissue expander placement at the time of mastectomy followed by radiation
therapy at Yale New Haven Hospital. Thirteen of those patients were excluded
because they chose to undergo autologous reconstruction instead of exchanging
their expanders for permanent implants following radiation therapy. An additional
five patients were excluded because their tissue expanders were permanently
removed prior to implant exchange, thus they did not complete the two-stage
expander-implant reconstruction. For patients who underwent bilateral breast
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reconstruction and received post-mastectomy radiation to both breasts, each
breast was recorded as an independent data point.

After exclusions, a total of fifty-five eligible patients were identified with fifty-six
breasts that underwent completed tissue expander-implant reconstruction and
received post-mastectomy radiation therapy.

Sequencing of Expander-Implant Exchange and Radiation

In order to address the first aim of this study, the impact of the sequencing of
expander-implant exchange on reconstructive outcomes, we divided our sample
into two cohorts: breasts that underwent expander-implant exchange prior to the
initiation of radiation therapy and breasts that underwent expander-implant
exchange after the completion of radiation therapy (figure 3). The primary
outcomes of interest were complications requiring additional, unplanned
operations and hospitalizations.

Breast Cancer
Diagnosis

Mastectomy/
Expander Placement

Expander-Implant
Exchange Before
Radiation

Expander-Implant
Exchange After
Radiation

Radiation

FIGURE 3. Sequencing of Expander-Implant Exchange and Radiation
The sample of eligible breasts was divided into two cohorts: those that underwent
expander-implant exchange before radiation (irradiating the permanent implant)
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and those that underwent expander-implant exchange after radiation (irradiating
the tissue expander).

Impact of Sequencing on Delivery of Radiation Therapy

For the second aim of this study, the impact of sequencing of expander-implant
exchange on delivery of radiation therapy, we excluded all patients who received
neoadjuvant chemotherapy, as its administration may impact the timing of postmastectomy adjuvant therapies. In the remaining patients, the number of days
from mastectomy/tissue expander placement to the initiation of radiation therapy
was recorded for comparison. The primary outcome of interest for this aim was
the number of days to initiation of radiation.

Timing of Expander-Exchange Following Radiation

For the third aim of this study, comparing the outcomes between early and late
expander-implant exchange following radiation completion, we only included
breasts that underwent expander-implant exchange after the completion of
radiation therapy. Breasts were then classified as having undergone exchange
early, less than 4 months after radiation, or late, more than 4 months after
radiation (figure 4). The time point of 4 months was chosen because it provided
groups of relatively equal size and characteristics for comparison. The primary
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outcomes of interest for this aim were complications requiring additional,
unplanned operations and hospitalizations.

Breast Cancer
Diagnosis

Exchange
< 4 months
After Radiation

Mastectomy/
Expander Placement

Exchange
> 4 months
After Radiation

Radiation

FIGURE 4. Timing of Expander-Implant Exchange After Radiation
The sample of eligible breasts that underwent expander-implant exchange after
radiation (irradiated tissue expanders) was divided into two cohorts: those that
underwent early exchange to permanent implant (within 4 months of completion
of radiation therapy) and those that underwent late exchange to permanent
implant (greater than 4 months after completion of radiation therapy)

All complications requiring additional surgery or hospitalization were recorded.
Complications included: cellulitis/prosthesis infection, wound dehiscence/implant
extrusion, seroma, hematoma, capsular contracture and suspected implant leak.
For the purposes of this study, we defined reconstruction failure as removal of
the permanent implant following initial successful expander-implant exchange.
Length of follow up was defined as the interval between date of
mastectomy/expander placement and date of last provider note.
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Statistical Analysis
Independent t-tests were performed to determine whether any significant
differences existed between the groups being compared. Additional statistical
analysis was performed using multivariate regression analysis, student’s t test
and Fischer exact test where appropriate. Statistical significance was
determined where p < 0.05. Analysis was performed using IBM SPSS Statistics
v20.0 software.

Contributions to Methods
The thesis author performed all aspects of this project including: thorough review
of the literature, preparation and submission of HIC documents, data collection,
database maintenance, and statistical analysis. In addition, I prepared an
abstract with data from this project that was accepted for an oral presentation at
the Northeastern Society of Plastic Surgeons in Boston, Massachusetts in
September 2012. I also prepared a manuscript of this study that has been
accepted for publication in an upcoming issue of Annals of Plastic Surgery.

14

III.

RESULTS

Sequencing of Expander-Implant Exchange and Radiation
From June 2004 – June 2011, a total of 56 two-stage tissue expander-implant
breast reconstruction surgeries were performed (by six different surgeons) that
also underwent radiation as part of their breast cancer treatment. Of these, 22
completed exchange for permanent implant prior to initiation of radiation
(irradiated their permanent implants) and 34 underwent exchange to permanent
implant following completion of radiation (irradiated their tissue expanders).
Patient characteristics can be found in Table A.

TABLE A: Patient Characteristics
Exchange Before
Radiation
(n = 22)
Age, mean (y)
48.1
2
BMI, mean (kg/m )
24.3
Race (n, %)
White
16 (72.7)
Black
4 (18.2)
Hispanic
2 (9.1)
Other
Smoking Status (n, %)
None
11 (50.0)
Former
6 (27.3)
Current
4 (18.2)
Comorbidities (n, %)
Diabetes
1 (4.6)
Hypertension
3 (13.6)
Follow Up Time, mean(mos)
46.0
* Denotes statistical significance

Exchange After
Radiation
(n = 34)
44.8
25.4

p
0.25
0.53
0.28

30 (88.2)
2 (5.9)
1 (2.9)
1 (2.9)
0.13
21 (61.8)
12 (35.3)
1 (2.9)
1 (2.9)
4 (11.8)
27.3

0.75
0.84
0.00*
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There was no statistical difference between two groups’ demographic data; the
cohorts were similar with respect to age at mastectomy, BMI, race, smoking
status, and comorbidities. The group that completed exchange following radiation
had a significantly shorter follow up time.
TABLE B: Oncologic and Treatment Characteristics
Exchange
Exchange After
Before Radiation
Radiation
(n = 22)
(n = 34)
Histology (n, %)
Infiltrating Ductal (IDC)
13 (59.1)
26 (76.5)
Infiltrating Lobular (ILC)
4 (18.2)
3 (8.8)
IDC with lobular features
2 (9.1)
4 (11.8)
IDC with tubular features
1 (4.6)
0 (0.0)
Mucinous carcinoma
0 (0.0)
1 (2.9)
Adenosquamous
1 (4.6)
0 (0.0)
Pathologic Stage (n, %)
0
0 (0.0)
3 (8.8)
1
1 (4.6)
1 (2.9)
2A
6 (27.3)
9 (26.5)
2B
11 (50.0)
11 (32.4)
3A
4 (18.2)
7 (20.6)
3B
0 (0.0)
3 (8.8)
Neoadjuvant Chemotherapy
(n, %)
8 (36.4)
17 (50)
Adjuvant Chemotherapy (n, %)
17 (77.3)
25 (73.5)
Chest Wall XRT (n, %)
22 (100.0)
34 (100.0)
Supraclavicular XRT (n, %)
19 (86.3)
29 (85.3)
Axilla XRT (n, %)
1 (4.6)
7 (20.6)
Internal Mammary XRT (n, %)
0 (0.0)
3 (8.8)
Scar Boost XRT (n, %)
0 (0.0)
1 (2.9)
Mastectomy (n, %)
Simple
11 (50.0)
10 (29.4)
Modified Radical
10 (45.5)
24 (70.6)
Unknown
1 (4.6)
0 (0.0)
Skin Sparing (n, %)
3 (13.6)
5 (14.7)
Nipple Sparing (n, %)
1 (4.6)
8 (23.5)
Implant Type – silicone (n, %)
9 (40.9)
28 (82.4)
ADM (n, %)
9 (40.9)
27 (79.4)
* Denotes statistical significance
ADM = acellular dermal matrix

p
0.29

0.41

0.32
0.75
1
0.80
0.10
0.15
0.42
0.09

0.91
0.06
0.00*
0.01*
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Oncologic and treatment characteristics of the two groups can be found above, in
Table B. The groups were similar in their oncologic characteristics including
tumor histology and cancer staging. Additionally, the two groups were similar in
the adjuvant therapies received. Of note, the group that completed exchange
following radiation had significantly higher use of both acellular dermal matrix
(ADM)2 and silicone implants during the reconstruction process.

The overall complication and reconstructive failure rates can be found in figure 3.
There was no significant difference between the two groups with respect to
overall complication rate (54.5% vs 47.1%, p = 0.58). The group that underwent
exchange after radiation experienced a higher reconstructive failure rate of
20.6% versus the 13.6% rate of reconstructive failure in the group that underwent
exchange before radiation; however, this difference was not statistically
significant.

2

Acellular dermal matrix (ADM) is a soft tissue lattice that is becoming more prevalent
in prosthetic based breast reconstruction. It is frequently employed as a sling or coverage
reinforcement, providing the tissue expander or implant with additional support within
the breast envelope.
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60.00%
50.00%

54.55%
47.06%

40.00%
30.00%

Exchange
Before
Radiation

20.00%

20.59%
13.64%

10.00%

Exchange After
Radiation

0.00%
Overall Complications
p = 0.584

Failure
p = 0.724

FIGURE 3: Overall Complication and Failure Rates
There was no statistically significant difference between the two groups with
respect to overall complication or reconstructive failure rate.

The complications requiring additional, unplanned surgery or hospitalization that
occurred in both groups included: infection, wound dehiscence/implant extrusion,
seroma, hematoma, capsular contracture, and suspected implant leak. The
specific break down of complications in each group can be found in Table C.
While there was no statistically significant difference between the two groups with
respect to infection, wound dehiscence, seroma or hematoma, the group that
underwent exchange prior to radiation, thus irradiating their permanent implant,
experienced a significantly higher incidence of capsular contracture (40.9% vs
11.8%, p<0.05) than the group that underwent exchange before radiation.
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TABLE C: Complications Necessitating Surgery/Hospitalization
Exchange
Exchange After
Before Radiation
Radiation
p
(n = 22)
(n = 34)
n
%
n
%
Infection
4
18.2
8
23.5
0.75
Wound Dehiscence/Extrusion
1
4.5
5
14.7
0.39
Seroma
0
0
1
2.9
1
Hematoma
0
0
2
5.9
0.51
Capsular Contracture
9
40.9
4
11.8 0.02*
Suspected Implant Leak
1
4.5
0
0
0.39
* Denotes statistical significance
The group that underwent exchange before radiation (irradiating the permanent
implant) experienced significantly more operative capsular contracture
complications (40.9% vs 11.8%, p = 0.02) than the group that underwent
exchange after radiation (irradiating the tissue expander).

The results of a multivariate logistic regression analysis to explore predictors of
experiencing complications can be seen in Table D. Of note, the sequencing of
exchange with relation to radiation did not increase the odds of developing a
complication (OR = 0.998, p = 0.998). The only variable associated with an
overall increased risk of experiencing a complication was current smoking activity
(OR = 14.866, p = 0.046).

TABLE D. Predictors of Complication Among All Patients
Variables
Odds Ratio
95% CI
Age
1.009
0.95-1.07
BMI
1.053
0.95-1.17
Current Smoker
14.866
1.04-211.64
Silicone Implant
4.670
0.88-24.70
Neoadjuvant Chemotherapy
0.194
0.05-0.74
Sequence of Expander-Implant Exchange
0.998
0.21-4.83
* Denotes statistical significance

P
0.774
0.338
0.046*
0.070
0.016*
0.998
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Impact of Sequencing on Initiation of Radiation Administration
In order to address our second aim, the impact of sequencing of expanderimplant exchange on delivery of radiation, we excluded all patients from our
sample that received neoadjuvant chemotherapy. This left 14 patients who
underwent exchange prior to radiation and 17 patients who underwent exchange
following radiation. Both groups underwent adjuvant chemotherapy following
mastectomy/tissue expander placement and prior to the initiation of radiation
therapy. In the group that experienced exchange after radiation, the initiation of
radiation therapy occurred an average of 188.0 days following mastectomy, while
the group that underwent exchange prior to radiation therapy experienced an
average of 220.4 days from mastectomy to initiation of radiation therapy,
representing a statistically significant difference. (Table E).

Table E. Impact of Sequencing on Delivery of Radiation
Exchange
Exchange After
Before Radiation
Radiation
(n = 14)
(n = 17)
Time to Radiation start,
mean (days)
220.4
*Denotes statistical significance

188.0

p

0.034*

Timing of Expander-Implant Exchange Following Radiation
To address the impact of timing of exchange following radiation, we only
examined the patients who underwent exchange to permanent implant following
radiation completion. Of those 34 patients, 20 underwent exchange to permanent
implant within 4 months (early) of completing radiation therapy and 14 underwent
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exchange to permanent implant greater than 4 months (late) following the
completion of radiation therapy. The average time between radiation completion
and exchange to permanent implant was 2.75 ± 0.76 months for the early group
and 7.25 ± 2.81months for the late group. Table F compares the patient and
treatment characteristics. The groups were similar in demographics,
comorbidities, and treatment characteristics.

TABLE F: Patient and Treatment Characteristics Across Early and Late
Exchange Groups
Early
Late
Exchange
Exchange
p
(n = 20)
(n = 14)
Age, mean (y)
47.1
41.6
0.13
BMI, mean (kg/m2)
26.0
24.5
0.55
Race (n, %)
0.68
White
17 (85.0)
13 (92.9)
Black
1 (5.0)
1 (7.1)
Hispanic
1 (5.0)
0 (0)
Other
1 (5.0)
0 (0)
Smoking Status (n, %)
0.31
None
14 (70.0)
7 (50.0)
Former
6 (30.0)
6 (42.9)
Current
0 (0)
1 (7.1)
Comorbidities (n, %)
Diabetes
1 (5.0)
0 (0)
1
Hypertension
3 (15.0)
1 (7.1)
0.63
Follow Up Time, mean(mos)
26.5
28.5
0.68
Time from PMRT to exchange, mean(mos)
2.83
7.35
0.00*
Neoadjuvant Chemotherapy (n, %)
10 (50.0)
7 (50.0)
1
Adjuvant Chemotherapy (n, %)
13 (65.0)
12 (85.7)
0.25
Implant Type – Silicone (n, %)
18 (90.0)
10 (71.4)
0.20
Alloderm (n, %)
16 (80.0)
11 (78.6)
1
*Denotes statistical significance
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In comparing the complications between early and late exchange, the group that
underwent early exchange had a 40% overall complication rate, whereas the
group that underwent late exchange had a 57.1% complication rate. This did not
represent a statistically significant difference. When looked at overall
reconstructive failure rate, the group that underwent early exchange had a 25%
failure rate while the group that underwent exchange late had a 14.3% failure
rate. Again, these differences were not found to be statistically significant.

60.00%
57.10%
50.00%
40.00%
40.00%
30.00%

Early Exchange

Late Exchange

25.00%

20.00%

14.30%

10.00%
0.00%
Overall Complications
p=0.487

Failure
p=0.672

FIGURE 4: Comparison of Overall Complication and Failure Rates Between
Early and Late Expander-Implant Exchange
There was no statistically significant difference in overall complication (40% vs
57.14%, p = 0.487) or reconstructive failure rate (25% vs 14.29%, p = 0.672).
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TABLE G: Complications Necessitating Surgery/Hospitalization Across
Early and Late Expander-Implant Exchange Groups
Early Exchange Late Exchange
(n = 20)
(n = 14)
p
n
%
n
%
Infection
6
30.0
2
14.3
0.42
Wound Dehiscence/Extrusion
3
15.0
2
14.3
1
Seroma
1
5.0
0
0
1
Hematoma
0
0
2
14.3
0.16
Capsular Contracture
1
5.0
3
21.4
0.28
*Denotes statistical significance
Analysis of specific complications using Fischer’s exact test can be seen in Table
G. When looking at the specific complications, there was no statistically
significant difference between the groups with respect to rate of infection, wound
dehiscence/extrusion, seroma, hematoma, or capsular contracture. Further
exploring the data trends, it is interesting to note that the group that underwent
exchange early experienced an infection rate of 30%, more than double the
14.3% infection rate seen in the group that underwent exchange late. Whereas,
the group that underwent exchange late had a 21.4% rate of capsular
contracture, four times the 5.0% rate of capsular contracture seen in the group
that underwent exchange early. Given the small numbers of the sample, neither
of these trends reached statistical significance.
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IV.

DISCUSSION

As the indications for adjuvant post-mastectomy therapy increase, we can
anticipate seeing an increase in the number of patients presenting for breast
reconstruction who will also undergo radiotherapy as part of their treatment.
While many have championed the use of autologous reconstruction to minimize
the high complication and reconstructive failure rates associated with irradiating
implants, implant-based reconstructions remain the most common form of
immediate breast reconstruction. Despite the increasing prevalence of this issue,
there remains a lack of consensus regarding the optimal timing and coordination
of radiation into the prosthetic reconstructive timeline. The purpose of this study
was to evaluate the relationship between expander-implant exchange and timing
of radiation administration, and how this relationship ultimately impacts
reconstruction complications in the context of two-stage tissue expander-implant
breast reconstruction.

Sequencing of Expander-Implant Exchange and Radiation

Our study represents one of the largest reported series investigating the impact
of sequencing of expander-implant exchange with relation to radiation therapy.
This report demonstrates that there is no statistically significant difference in
overall complication or reconstructive failure rates if the exchange to permanent
implant is performed before or after radiation, thus we were unable to reject our
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initial null hypothesis. However, we did find that sequencing may impact the type
of complication experienced, as our results indicated that patients who
underwent exchange prior to radiation, thus irradiating their permanent implants.
experienced a higher incidence of capsular contracture necessitating additional
operative interventions.

The higher incidence of capsular contracture could possibly be explained by the
fact that during most expander-implant exchange operations, a capsulotomy or
capsulectomy is performed. A capsulotomy is a procedure in which the capsule
(scar tissue that surrounds the tissue expander or implant) is surgically released.
In a capsulectomy, the entire capsule is surgically removed. All patients who
undergo prosthetic reconstruction develop some form of a capsule; it is the result
of the body’s normal physiologic immune response when presented with a
foreign body. The capsule itself can be beneficial in supporting the expander or
implant, helping to preserve breast shape and maintain breast projection.
However, capsular contracture is a pathologic process that occurs when excess
scar tissue develops, resulting in a physically painful, firm, and aesthetically
displeasing breast. Radiation significantly increases the risk of developing
capsular contracture. For patients that underwent exchange to permanent
implant after radiation, any pathologic capsular formation that occurred
surrounding the tissue expander could have been addressed at the time of the
exchange to permanent implant, circumventing the need for an additional,
unplanned operation. In the patients who underwent exchange prior to radiation,
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thus irradiating their permanent implant, the only way to address any radiationinduced capsule formation was through an additional, unplanned capsulotomy or
capsulectomy procedure.

Previous single center studies that have attempted to investigate the impact of
sequencing of expander-implant exchange related to radiation have yielded
variable and inconsistent results. The majority of these studies have been
retrospective in nature and limited by a small number of patients. Furthermore,
most single center studies have been limited by their own institutional protocols
regarding sequencing, resulting in the publication of outcomes related to
irradiating tissue expanders or outcomes related to irradiating permanent
implants, with very few studies directly comparing the two.

Ascherman et al. explored the outcomes of patients who underwent two-stage
expander-implant breast reconstruction, comparing groups that underwent
neoadjuvant radiotherapy prior to mastectomy and groups that underwent
radiotherapy during the tissue expander stage to patients who did not receive
any radiotherapy at all. There was no analysis of patients who underwent
radiation therapy to a permanent implant. Their finding of a 40.7% overall
complication rate included both neoadjuvant radiation and adjuvant radiation
groups. Based on this, they concluded that there is an overall increase in
complications associated with radiation and prosthetic breast reconstruction.
However, their analysis did not provide additional information regarding the
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optimal timing of radiotherapy(11). Lin et al. found comparable 43.8% and 41.2%
complication rates in patients who underwent neoadjuvant radiotherapy and
adjuvant radiotherapy prior to exchange, respectively(24).

Cordeiro and McCarthy’s analysis of tissue expander-implant outcomes included
29 patients who received neoadjuvant radiotherapy and 62 patients who were
irradiated after expander-implant exchange. Their findings included a statistically
significant increase in capsular contracture in patients who were irradiated after
exchange as compared to patients who received neoadjuvant radiation (50.1%
vs 20%)(25). Our findings of increased incidence of capsular contracture in
patients who undergo exchange prior to radiation are consistent with this prior
report.

Nava et al. conducted the largest retrospective study investigating the
sequencing of exchange, consisting of 109 patients who underwent exchange
prior to radiation therapy and 50 patients who underwent exchange following
radiation therapy. Their results showed a statistically significant difference in
complication and failure rate between the two groups with a 6.4% failure rate for
exchange prior to radiation and 40% failure rate for exchange following radiation,
contrary to our results which suggested that there is no difference in overall
complication or failure rate with respect to radiotherapy sequencing(19). Of note,
our study only included patients who had completed both stages of tissue
expander-implant reconstruction, whereas the Nava study included patients who
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had their reconstructions fail during the tissue expander stage and patients who
opted for autologous reconstruction instead of an implant following tissue
expansion. If we had included the patients who experienced failure during the
tissue expander stage and patients who chose to undergo autologous
reconstruction following undergoing radiation to their tissue expanders, we also
would have seen a much higher complication and failure rate in the group that
underwent exchange to permanent implants after radiation completion.

Of note, when we performed our multivariate regression analysis, examining the
variables that could be predictors of increased complications, sequencing of the
expander-exchange was not associated with worse outcomes. The only variable
that was associated with worse outcomes was smoking. This finding is consistent
with the literature. In Petersen et al.’s 2012 retrospective study of 208 prosthetic
breast reconstruction patients found smoking to be the most significant risk factor
for infection and post-operative complications(26).

The limitations of this report include the retrospective nature of the study. With
retrospective reviews of this nature, we are limited in the amount and variability
of information provided in the medical record. While our numbers reflect one of
the largest series to investigate this question, there remained areas where
statistical significance was not achieved. Performing a power analysis based on
our results indicated that in order to observe the 7% difference in failure rate with
80% power, we would need an n of 390 patients in each group. No previous
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single institution study that has explored this subject has reached this sample
size, suggesting that a multi-institutional study may be the best way to answer
this question in the future.

Additionally, we only included patients who had completed two-stage expanderimplant reconstruction. By excluding both patients who experienced failure or
permanent removal of their tissue expander without undergoing implant
reconstruction and patients who opted to undergo flap reconstruction following
tissue expander radiation, it is possible that we minimized the actual complication
rate experienced in the irradiated tissue expander group.

The mastectomies and breast reconstruction operations were performed by a
number of different surgeons. Reconstructive surgeon preference has a
significant impact on the time course of when operations occur with two-stage
expander-implant breast reconstructions. However, our total sample size was too
small to control for the impact of surgeon bias.

Impact of Sequencing on Initiation of Radiation Administration

From an oncologic viewpoint, radiation oncologists would prefer to initiate
radiation therapy as soon as possible following mastectomy. The results of our
study indicated a statistically significant delay of 32 days in the initiation of postmastectomy radiation therapy administration when the exchange procedure
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occurs prior to radiation start. The clinical significance of this delay is not
currently known. Prior studies examining the impact of immediate breast
reconstruction on oncologic outcomes have indicated acceptable disease
control(27). This is the first study to examine the impact of sequencing of implant
exchange on initiation of adjuvant radiation.

Logically, it makes sense that there would be a delay when performing the
exchange prior to radiation administration. Typically, radiation oncologists will not
proceed with radiation administration until a patient is well healed postoperatively. Furthermore, if there are any signs of infection or wound
complications following the operation, this could further delay the start of
radiation administration as it would add additional days or even weeks until the
skin is satisfactorily healed enough to begin radiation therapy.

Timing of Expander-Implant Exchange Following Radiation

The duration of time to wait following radiation completion before proceeding with
expander-implant exchange remains a question of clinical judgment for most
surgeons. For patients who will not receive radiation, the literature is supportive
of proceeding with exchange to permanent implants as early as 1 month
following the completion of expansion (28, 29). Understandably, the addition of
radiation complicates this timeline, and current recommendations range from
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waiting anywhere from 3-6 months following radiation completion before
proceeding with additional reconstructive operations (28, 30, 31).

While our results suggest that there is no difference in overall complication or
failure rates between groups who underwent exchange <4 months and >4
months following radiation therapy, there does appear to be a trend in the types
of complications, with respect to the time of exchange. Patients who underwent
exchange earlier had a higher incidence of cellulitis, whereas patients who
underwent exchange later had a higher incidence of capsular contracture.

The pathophysiology of radiotherapy’s effects on skin and soft tissue may explain
these differences in complication type. The acute changes related to radiation
occur within the first 70 days following radiation administration. They include
erythema, skin reactions, and moist desquamation. All of which may leave the
skin more susceptible to infection and possible cellulitis. The later effects of
radiation are related to dermal injury and include tissue atrophy, subcutaneous
fibrosis and necrosis, which may contribute toward the higher rates of capsular
contracture seen in patients who underwent exchange later.(32)

Most recently, in 2012, Peled et al., were the first to explore this question of
timing of exchange following radiation in the literature, comparing the failure rates
of 88 patients who underwent expander-implant exchange less than 6 months
after completion of post-mastectomy radiation therapy to 39 patients who
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underwent exchange at least 6 months following post-mastectomy radiation
therapy. Contrary to our findings, their results indicated a statistically significant
increase in failure of 22.4% vs 7.7%, p = 0.036, in the group undergoing
exchange earlier. Additionally, when they further subdivided the time interval of
exchange following radiation, they found the highest rate of failure, 28.6%, in the
group that underwent exchange less than 3 months following radiation
completion as compared to the 17.9% failure rate in the group that underwent
exchange between 3 to 6 months following radiation completion.(31) Our
findings also indicated a higher failure rate in the group that underwent
reconstruction earlier (25% vs 14.29%), however these results did not reflect a
significant difference. It is possible that as our numbers increase, this difference
may become more pronounced, and we would be able to draw similar
conclusions. Additionally, implant exchange occurred sooner following radiation
completion at our institution with a mean time between radiation and exchange to
permanent implant of 2.75 months and 7.25 months in our study, while their
study had a mean time between radiation completion and exchange of 3.4
months and 8.6 months.

The small sample size of our study limited the power of our generated results,
and we were unable to reach significance when we were comparing specific
complications between groups. In order to obtain a better understanding
regarding the impact of timing of exchange following radiation completion on
outcomes, it would be necessary to perform a larger study with an greater
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number of patients in each group. Performing a power calculation based on
these results indicated that in order to see the 12% difference in failure rate with
80% power, we would need an n of 176 patients in each group. Again, this
would be another question that may be better served by performing a multiinstitutional study, where we’re able to analyze outcomes from a greater pool.

As mentioned previously, the fact that our study contained the results of six
surgeons, as opposed to solely examining the outcomes of a single surgeon
introduced some degree of surgeon bias into this study. The decision on when to
proceed with expander-implant exchange following radiation is largely at the
surgeon’s discretion, and many have well developed preferences of which they
follow. Our sample size was too small to control for this factor.
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CONCLUSION

Our findings suggest that neither the sequencing nor the timing of expanderimplant exchange in the setting of post-mastectomy radiation therapy has an
impact on overall complication or reconstruction failure rate. The timing of
exchange, however, may have an influence on the types of complications
experienced by patients. Performing implant exchange prior to radiation, and
thus radiating a permanent implant, results in a higher incidence of capsular
contracture, necessitating additional surgical revisions.

The sequencing of expander-implant exchange does impact the start time of
radiation therapy administration. Performing the exchange prior to radiation can
result in a delay of initiation of adjuvant therapy.

Additionally, while there was no difference in overall complication or
reconstructive failure rates with respect to timing of exchange following
completion of radiation, there may be an association with different types of
complications depending on the timing of exchange. Performing exchange to
permanent implant earlier following the completion of radiation therapy may
result in increased risk of infectious related complications, whereas performing
exchange later following the completion of radiation therapy may result in an
increased risk of fibrotic related complications.
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Ultimately, the management of breast cancer today requires the collaboration of
a team of doctors from varying specialties in order to optimize both oncologic
outcomes and reconstructive results. All patients who are presenting with newly
diagnosed breast cancer should be provided with information regarding the
various treatment modalities and all available reconstruction options. Patients
should also be made aware of the impact that adjuvant therapies can have on
reconstructive outcomes.
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